ASAH1 and Fabry disease: Using the Asah1tmEx1 model, a follow-up study by Beckmann et al. investigated acid sphingomyelinase (Asm), a lysosomal enzyme upstream of ACDase that synthesizes Cers, as a potential therapeutic target for FD [45].